The pipeline focus at BiotechSino is developing therapeutic monoclonal antibodies (mAbs) which target
infectious diseases. BiotechSino also poised to enter the immune-oncology space with new products that
aim to fight cancer and autoimmune disease. The current pipeline is a balance of both clinically validated
as well as novel targets.
Some targets have been partnered with top biopharmaceutical companies.